Esthesioneuroblastomas are rare, soft-tissue tumors that can often extend from the sinonasal cavity into the intracranial and orbital space. Prognosis depends upon the histological grade and location/extent of the tumor. Treatment often consists of maximum surgical resection followed by adjuvant chemoradiation therapy. We present a case of a patient with esthesioneuroblastoma accompanied by an extensive osteoblastic reaction leading to a significant hyperostosis along the skull base. His presenting symptoms included diplopia, and imaging revealed invasion of the orbital and intracranial spaces. Although a gross total resection of the soft tissue component of the tumor was achieved, a complete removal of the involved hyperostotic skull base could not be performed despite endoscopic endonasal and bifrontal craniotomy approaches in the same operative setting. Symptomatically, the patient improved and went on to receive chemoradiation therapy; he remained clinically and radiographically stable at 12 months. Investigation into the genetics and immunohistochemistry of this rare, hyperostotic variant of esthesioneuroblastoma may provide details regarding its aggressive nature.
Introduction
The choroid is a rare site of involvement by metastatic carcinomas. The literature that is available regarding the management of this complication is limited, especially with respect to the effectiveness of systemic chemotherapy without external beam radiation treatment (EBRT). This case of bilateral choroidal metastases demonstrates a very rare initial presentation of nonsmall cell lung cancer and highlights the potential benefits of systemic chemotherapy as a monotherapeutic approach to achieve choroidal metastasis regression.
Case presentation
A 59-year-old man presented to our ophthalmology clinic with flashes and decreased vision in his left eye. His past medical history was significant for a total thyroidectomy of a benign thyroid adenoma and a 10 pack-year smoking history. Ophthalmic examination revealed visual acuity scan showed increased FDG uptake in the lung nodules and mediastinal lymph nodes.
Biopsy of the adrenal nodule showed a moderately differentiated adenocarcinoma. Immunohistochemistry included stains for cytokeratins (CK) and thyroid transcription factor-1 (TTF-1). Staining was positive for TTF-1 and was negative for CK-19 and CK-20. The negative staining for CK-19 and CK-20 ruled out malignancy of the pancreaticobiliary and colon, respectively, whereas expression of TFF-1 suggested a malignancy of the lung [4] . The patient began palliative chemotherapy with carboplatin and pemetrexed. Over the patient's course, the chorodial lesions in the right and left eyes decreased by 25% following one round of chemotherapy. The visual acuity improved to 20/40 in the right eye and 20/50 in the left eye. However, the primary lung cancer continued to progress and the patient was hospitalized several times for malignant pleura and pericardial effusions.
Discussion
The choroid is a rare site of involvement by metastatic carcinomas. Godtfredsen reported only six patients (0.07%) in a survey that included 8,712 patients with malignancy [3] .
Metastasis to the choroid has previously been associated with breast and lung cancer, typically occurring late in the disease course. However, choroidal metastasis as the primary presentation of metastatic lung cancer is very rare and has only been reported in 56 cases of which only four of those had bilateral metastases as seen in this case [5] . Previous studies have shown that combination chemotherapy (bevacizumab or carboplatin and pemetrexed) and external beam radiation therapy (EBRT) result in lesion reemission in 85-93% of patients [1, 5] . In this case, systemic therapy with carboplatin and pemetrexed without radiation therapy achieved choroidal metastasis regression and an improvement in visual acuity. The available literature on the effectiveness of systemic chemotherapy without EBRT is limited. However, one case report showed that complete remission of choroidal metastases from nonsmall cell lung cancer was achieved following three cycles of carboplatin, gemcitabine, and bevacizumab without EBRT [2] .
Conclusion
This case of bilateral choroidal metastasis demonstrates a very rare initial presentation of nonsmall cell lung cancer and highlights the potential benefits of systemic chemotherapy as a monotherapeutic approach to achieve choroidal metastasis regression.
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